BridgeBio Pharma, Inc. (BBIO): Price and Financial Metrics


BridgeBio Pharma, Inc. (BBIO)

Today's Latest Price: $27.85 USD

0.15 (0.54%)

Updated Aug 6 6:55pm

Add BBIO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BBIO Stock Summary

  • BridgeBio Pharma Inc's stock had its IPO on June 27, 2019, making it an older stock than just 0.5% of US equities in our set.
  • With a price/sales ratio of 81.99, BridgeBio Pharma Inc has a higher such ratio than 96.87% of stocks in our set.
  • With a year-over-year growth in debt of 761.32%, BridgeBio Pharma Inc's debt growth rate surpasses 97.6% of about US stocks.
  • Stocks that are quantitatively similar to BBIO, based on their financial statements, market capitalization, and price volatility, are DCPH, ORMP, CYTK, FOLD, and BGNE.
  • Visit BBIO's SEC page to see the company's official filings. To visit the company's web site, go to bridgebio.com.
BBIO Daily Price Range
BBIO 52-Week Price Range

BBIO Stock Price Chart Technical Analysis Charts


BBIO Price/Volume Stats

Current price $27.85 52-week high $48.36
Prev. close $27.70 52-week low $14.23
Day low $27.00 Volume 248,200
Day high $28.22 Avg. volume 770,561
50-day MA $30.48 Dividend yield N/A
200-day MA $30.56 Market Cap 3.40B

BridgeBio Pharma, Inc. (BBIO) Company Bio


BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.





BBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

BBIO Latest Social Stream


Loading social stream, please wait...

View Full BBIO Social Stream

Latest BBIO News From Around the Web

Below are the latest news stories about BridgeBio Pharma Inc that investors may wish to consider to help them evaluate BBIO as an investment opportunity.

Heron's Cinvanti Progress, And Other News: The Good, Bad And Ugly Of Biopharma

Heron Therapeutics Advances Phase 2 Study of CINVANTI Heron Therapeutics Inc. (HRTX) announced that it has started its Phase 2 clinical study of CINVANTI. The company has started the trial after receiving a go-ahead from the FDA for its Investigational New Drug application for the drug candidate for treating COVID-19....

Avisol Capital Partners on Seeking Alpha | July 17, 2020

Mid-stage study underway on BridgeBio's infigratinib for bone growth disorder

The first subject has been dosed in a Phase 2 clinical trial, PROPEL 2, evaluating BridgeBio Pharma's (BBIO) infigratinib (BBP-831) children with achondroplasia, a bone growth disorder characterized by dwarfism.The primary efficacy measure is the change from baseline in annualized height velocity up to month 18.The estimated primary completion date...

Seeking Alpha | July 15, 2020

BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia

SAN FRANCISCO, July 15, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that the first child with achondroplasia has been dosed with.

Yahoo | July 15, 2020

BridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual Meeting

BOSTON, July 10, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Phoenix Tissue Repair (PTR) today announced an upcoming presentation of interim data from an ongoing.

Yahoo | July 10, 2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., July 06, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on July.

Yahoo | July 6, 2020

Read More 'BBIO' Stories Here

BBIO Price Returns

1-mo -11.50%
3-mo -18.18%
6-mo -20.42%
1-year -6.61%
3-year N/A
5-year N/A
YTD -20.54%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8283 seconds.